Table 1.
Clinical and immunophenotypical characteristics of DLBCL patients
| Features | No. of Patients (%) |
|---|---|
| Age (years) | 62 |
| < 60 | 31 (38) |
| ≥ 60 | 51 (62) |
| Sex Male/Female | 48 /34 (59/41) |
| IPI | |
| 0–2 | 42 (51) |
| ≥ 3 | 40 (49) |
| IPI Age adjusted (IPIaa) | |
| 0 | 17 (21) |
| 1 | 27 (33) |
| 2 | 20 (24) |
| 3 | 18 (22) |
| Ann Arbor stage | |
| I/II | 29 (35) |
| III/IV | 53 (65) |
| Serum lactate dehydrogenase (>1x normal) | 41 (51) |
| Pathological type | |
| GCB | 49 (60) |
| Non-GCB | 33 (40) |
| Therapy regimen | R-CHOP |
| Median follow-up time, months | 53.7 (0.4–202.6) |
| 5-year OS | 65.9 |
| 5-year PFS | 60.6 |